Stockscreener 앱 받기
1.04
0.97%
0.01
시간 외 거래:
1.05
0.01
+0.96%
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech Granted Two Additional U.S. Patents For Annamycin - marketscreener.com
Moleculin secures two new US patents for cancer drug Annamycin By Investing.com - Investing.com India
Moleculin Biotech Secures Two New U.S. Patents - TipRanks
Moleculin secures two new US patents for cancer drug Annamycin - Investing.com Australia
Moleculin Biotech (MBRX) Secures New Patents for Annamycin Innovation | MBRX Stock News - GuruFocus
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents | MBRX Stock News - GuruFocus
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents - GlobeNewswire
Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Friday - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Moleculin Biotech (MBRX) Reveals Promising Data for Annamycin at - GuruFocus
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstr - GuruFocus
Moleculin Biotech Unveils Promising Annamycin Data at AACR - TipRanks
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer | MBRX Stock News - GuruFocus
Moleculin Biotech Presents Promising Annamycin Data at AACR Annual Meeting 2025, Highlighting Synergistic Potential with FDA Approved Cancer Therapies - Nasdaq
Moleculin reports Annamycin cancer drug synergy at AACR meeting By Investing.com - Investing.com UK
Moleculin Announces New Pre-Clinical Data for Annamycin - GlobeNewswire
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Groundbreaking Cancer Drug Data: Annamycin Demonstrates Effectiveness Against Multiple Cancer Types - Stock Titan
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) - ADVFN
Moleculin Biotech Releases Corporate Presentation Online - TipRanks
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) - Aktiellt
Moleculin Biotech’s Annamycin Highlighted at AACR 2025 - TipRanks
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 | MBRX Stock News - GuruFocus
Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire
Major Cancer Research Breakthrough: Moleculin's Annamycin Drug Combinations Study Heads to AACR 2025 - Stock Titan
Moleculin Announces Acceptance of Abstract to be Presented at th - GuruFocus
Moleculin Biotech adjourns special meeting due to lack of quorum - Investing.com Australia
Moleculin Biotech adjourns special meeting due to lack of quorum By Investing.com - Investing.com South Africa
Moleculin Reports Second Quarter 2023 Financial Results - Seeking Alpha
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks
Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener
Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan
Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN
What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World
Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World
Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN
Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq
Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World
H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com
Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
0.39%
3.66%
자본화:
|
볼륨(24시간):